Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q4 2016 · 10-K
Revenue$39.00M$39.00M±0.0% vs Q4 2015 Net Income-$27.39M-$27.39MN/M vs Q4 2015 EPS Diluted$0.03$0.03±0.0% vs Q4 2015 Gross Profit$5,420,000±0.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$15,767,000N/M Free Cash Flowderived-$16,214,000N/M Margins · derivedGross margin13.9%±0.0 pt vs Q4 2015
Operating margin-57.9%−71.9 pt vs Q4 2015
Net margin-70.2%±0.0 pt vs Q4 2015
ended Dec 31, 2016 · filed Feb 28, 2017 · 59 d after period end